Esra AYDEMİR COBAN, Didem TECİMEL, Ezgi KASİKCİ, Omer Faruk BAYRAK, Fikrettin SAHİN

E-cadherin might be a stage-dependent modulator in aggressiveness in pancreatic cancer cells

Pancreatic ductal adenocarcinoma (PDAC) pathology is known for its uncontrollable progress due to highly invasive characteristics and refractory behavior against existing chemotherapies. The aberrant expression of CDH1 (expresses the protein E-cadherin) is associated with increased overall survival in various cancers, however, E-cadherin expression in PDAC progression has remained elusive. We investigated the impact of exogenously elevated E-cadherin levels on the tumorigenicity of transduced low grade and metastatic PDAC cell lines, Panc-1 and AsPC-1, respectively. Constitutive expression of E-cadherin promoted a more hybrid E/M state in AsPC-1 cells, while it was associated with the acquisition of a more epithelial-like state in Panc1 cells. Our study suggests that E-cadherin may play differential roles in determining the metastatic characteristics of primary and metastatic pancreatic cancer cells.

Keywords:

Panc-1, AsPC1, E-cadherin, CRISPR/dCas9 activation, pancreas cancer,

PDF

___

Aparicio LA, 2012, CANCER METAST REV, V31, P375, DOI 10.1007/s10555-012-9348-x
Bhagwandin VJ, 2009, BBA-MOL BASIS DIS, V1792, P248, DOI 10.1016/j.bbadis.2009.02.007
Chao YL, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-179
CHEN WH, 1982, IN VITRO CELL DEV B, V18, P24
De Santis G, 2009, ONCOGENE, V28, P1206, DOI 10.1038/onc.2008.470
Fang DX, 2007, J BIOL CHEM, V282, P11221, DOI 10.1074/jbc.M611871200
Heuberger J, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a002915
Jolly MK, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00155
Kroger C, 2019, P NATL ACAD SCI USA, V116, P11553, DOI 10.1073/pnas.1907473116
Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30
Moletta L, 2019, CANCERS, V11, DOI 10.3390/cancers11070991
Pece S, 1999, J BIOL CHEM, V274, P19347, DOI 10.1074/jbc.274.27.19347
Petrova YI, 2016, MOL BIOL CELL, V27, P3233, DOI 10.1091/mbc.E16-01-0058
Pires BRB, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169622
Quinn SN, 2017, MOL CARCINOGEN, V56, P1344, DOI 10.1002/mc.22598
Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143
Rosivatz E, 2004, INT J CANCER, V111, P711, DOI 10.1002/ijc.20317
Smigiel JM, 2018, CANCERS, V10, DOI 10.3390/cancers10010014
Song YZ, 2019, MOL THER-ONCOLYTICS, V14, P130, DOI 10.1016/j.omto.2019.04.005
Swayden M, 2018, HELIYON, V4, DOI 10.1016/j.heliyon.2018.e01055
Weidenfeld K, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00381
Xu WT, 2015, CELL ADHES MIGR, V9, P317, DOI 10.1080/19336918.2015.1016686
Yan YM, 2016, CANCER RES, V76, P2419, DOI 10.1158/0008-5472.CAN-15-1691
Zammarchi F, 2011, AM J PATHOL, V178, P361, DOI 10.1016/j.ajpath.2010.11.021
Zhang JN, 2013, NEURAL DEV, V8, DOI 10.1186/1749-8104-8-7
Zhang Y, 2018, FRONT MED-PRC, V12, P361, DOI 10.1007/s11684-018-0656-6
Zhu ZL, 2018, CELL PHYSIOL BIOCHEM, V46, P238, DOI 10.1159/000488426